{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:38:05Z","timestamp":1792442285445,"version":"4.5.0"},"reference-count":106,"publisher":"European Respiratory Society (ERS)","issue":"168","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2023,6,30]]},"abstract":"<jats:p>\n                    Bronchiectasis is a common progressive respiratory disease with recognisable radiological abnormalities and a clinical syndrome of cough, sputum production and recurrent respiratory infections. Inflammatory cell infiltration into the lung, in particular neutrophils, is central to the pathophysiology of bronchiectasis. Herein we explore the roles and relationships between infection, inflammation and mucociliary clearance dysfunction in the establishment and progression of bronchiectasis. Microbial and host-mediated damage are important processes underpinning bronchiectasis and the relative contribution of proteases, cytokines and inflammatory mediators to the propagation of inflammation is presented. We also discuss the emerging concept of inflammatory endotypes, defined by the presence of neutrophilic and eosinophilic inflammation, and explore the role of inflammation as a treatable trait. Current treatment for bronchiectasis focuses on treatment of underlying causes, enhancing mucociliary clearance, controlling infection and preventing and treating complications. Data on airway clearance approaches\n                    <jats:italic>via<\/jats:italic>\n                    exercise and mucoactive drugs, pharmacotherapy with macrolides to decrease exacerbations and the usefulness of inhaled antibiotics and bronchodilators are discussed, finishing with a look to the future where new therapies targeting host-mediated immune dysfunction hold promise.\n                  <\/jats:p>","DOI":"10.1183\/16000617.0015-2023","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T04:30:20Z","timestamp":1686112220000},"page":"230015","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":71,"title":["Basic, translational and clinical aspects of bronchiectasis in adults"],"prefix":"10.1183","volume":"32","author":[{"given":"James D.","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-2569","authenticated-orcid":false,"given":"Catherine M.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"2024102404130100000_32.168.230015.1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0041-1730891","article-title":"Pathophysiology of bronchiectasis","volume":"42","author":"Keir","year":"2021","journal-title":"Semin Respir Crit Care Med"},{"key":"2024102404130100000_32.168.230015.2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"key":"2024102404130100000_32.168.230015.3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/resp.12595","article-title":"Secreted mucins and airway bacterial colonization in non-CF bronchiectasis","volume":"20","author":"Sibila","year":"2015","journal-title":"Respirology"},{"key":"2024102404130100000_32.168.230015.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201210-1937OC"},{"key":"2024102404130100000_32.168.230015.5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.chest.2020.02.048","article-title":"Increased chitotriosidase is associated with Aspergillus and frequent exacerbations in South-East Asian patients with bronchiectasis","volume":"158","author":"Poh","year":"2020","journal-title":"Chest"},{"key":"2024102404130100000_32.168.230015.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00766-2018"},{"key":"2024102404130100000_32.168.230015.7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.chest.2021.02.019","article-title":"The association of long-term macrolide therapy and nontuberculous mycobacterial culture positivity in patients with bronchiectasis","volume":"160","author":"Metersky","year":"2021","journal-title":"Chest"},{"key":"2024102404130100000_32.168.230015.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00149805"},{"key":"2024102404130100000_32.168.230015.9","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-13-49"},{"key":"2024102404130100000_32.168.230015.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00097014"},{"key":"2024102404130100000_32.168.230015.11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/iai.51.1.115-118.1986","article-title":"Specific cleavage of human type III and IV collagens by Pseudomonas aeruginosa elastase","volume":"51","author":"Heck","year":"1986","journal-title":"Infect Immun"},{"key":"2024102404130100000_32.168.230015.12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1128\/iai.54.1.149-153.1986","article-title":"Degradation of soluble laminin and depletion of tissue-associated basement membrane laminin by Pseudomonas aeruginosa elastase and alkaline protease","volume":"54","author":"Heck","year":"1986","journal-title":"Infect Immun"},{"key":"2024102404130100000_32.168.230015.13","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2010.066"},{"key":"2024102404130100000_32.168.230015.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00612-2017"},{"key":"2024102404130100000_32.168.230015.15","doi-asserted-by":"publisher","DOI":"10.11150\/kansenshogakuzasshi1970.68.138"},{"key":"2024102404130100000_32.168.230015.16","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01137-19"},{"key":"2024102404130100000_32.168.230015.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0487OC"},{"key":"2024102404130100000_32.168.230015.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201102-0236OC"},{"key":"2024102404130100000_32.168.230015.19","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.3.9606120"},{"key":"2024102404130100000_32.168.230015.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1092385"},{"key":"2024102404130100000_32.168.230015.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200808-1250OC"},{"key":"2024102404130100000_32.168.230015.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201712-2423OC"},{"key":"2024102404130100000_32.168.230015.23","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.008037"},{"key":"2024102404130100000_32.168.230015.24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30504-X","article-title":"Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study","volume":"9","author":"Keir","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102404130100000_32.168.230015.25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00484"},{"key":"2024102404130100000_32.168.230015.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023637"},{"key":"2024102404130100000_32.168.230015.27","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00403-18"},{"key":"2024102404130100000_32.168.230015.28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000675"},{"key":"2024102404130100000_32.168.230015.29","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00660-10"},{"key":"2024102404130100000_32.168.230015.30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1223012"},{"key":"2024102404130100000_32.168.230015.31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.9.4725"},{"key":"2024102404130100000_32.168.230015.32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17476348.2018.1475235","article-title":"CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease","volume":"12","author":"Fernandez Fernandez","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"2024102404130100000_32.168.230015.33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83922"},{"key":"2024102404130100000_32.168.230015.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-1946-7"},{"key":"2024102404130100000_32.168.230015.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201301-0059CI"},{"key":"2024102404130100000_32.168.230015.36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/jcm3020491","article-title":"Genetic testing in the diagnosis of primary ciliary dyskinesia: state-of-the-art and future perspectives","volume":"3","author":"Collins","year":"2014","journal-title":"J Clin Med"},{"key":"2024102404130100000_32.168.230015.37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fped.2017.00135","article-title":"Primary ciliary dyskinesia: an update on clinical aspects, genetics, diagnosis, and future treatment strategies","volume":"5","author":"Mirra","year":"2017","journal-title":"Front Pediatr"},{"key":"2024102404130100000_32.168.230015.38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/17476348.2022.2100350","article-title":"Epithelial damage in the cystic fibrosis lung: the role of host and microbial factors","volume":"16","author":"Glasgow","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"2024102404130100000_32.168.230015.39","first-page":"1309746","article-title":"Airway epithelium dysfunction in cystic fibrosis and COPD","volume":"2018","author":"De Rose","year":"2018","journal-title":"Mediators Inflamm"},{"key":"2024102404130100000_32.168.230015.40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01910-2017"},{"key":"2024102404130100000_32.168.230015.41","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2002.129847"},{"key":"2024102404130100000_32.168.230015.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301725"},{"key":"2024102404130100000_32.168.230015.43","doi-asserted-by":"publisher","DOI":"10.1186\/rr29"},{"key":"2024102404130100000_32.168.230015.44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1516"},{"key":"2024102404130100000_32.168.230015.45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006565"},{"key":"2024102404130100000_32.168.230015.46","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"},{"key":"2024102404130100000_32.168.230015.47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03156-2020"},{"key":"2024102404130100000_32.168.230015.48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00300-2022"},{"key":"2024102404130100000_32.168.230015.49","doi-asserted-by":"crossref","first-page":"2100025","DOI":"10.1183\/13993003.00025-2021","article-title":"Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis","volume":"58","author":"McLeese","year":"2021","journal-title":"Eur Respir J"},{"key":"2024102404130100000_32.168.230015.50","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404130100000_32.168.230015.51","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-2600(18)30053-5","article-title":"Bronchiectasis: new therapies and new perspectives","volume":"6","author":"Chalmers","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102404130100000_32.168.230015.52","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00777-2021"},{"key":"2024102404130100000_32.168.230015.53","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201309-1575OC"},{"key":"2024102404130100000_32.168.230015.54","first-page":"2003390","article-title":"Task force report: European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis","volume":"56","author":"Chang","year":"2021","journal-title":"Eur Respir J"},{"key":"2024102404130100000_32.168.230015.55","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00176-2022"},{"key":"2024102404130100000_32.168.230015.56","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01441-2020"},{"key":"2024102404130100000_32.168.230015.57","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.chest.2020.06.050","article-title":"Airway clearance techniques in bronchiectasis: analysis from the United States bronchiectasis and non-TB mycobacteria research registry","volume":"158","author":"Basavaraj","year":"2020","journal-title":"Chest"},{"key":"2024102404130100000_32.168.230015.58","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01926-2017"},{"key":"2024102404130100000_32.168.230015.59","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205587"},{"key":"2024102404130100000_32.168.230015.60","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1164\/rccm.201910-1972OC","article-title":"Relationship between symptoms, exacerbations, and treatment response in bronchiectasis","volume":"201","author":"Gao","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404130100000_32.168.230015.61","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102404130100000_32.168.230015.62","doi-asserted-by":"crossref","first-page":"102095","DOI":"10.1016\/j.pupt.2021.102095","article-title":"The immunomodulatory effects of macrolide antibiotics in respiratory disease","volume":"71","author":"Pollock","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"key":"2024102404130100000_32.168.230015.63","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03390-2020"},{"key":"2024102404130100000_32.168.230015.64","doi-asserted-by":"crossref","first-page":"2001451","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"Loebinger","year":"2021","journal-title":"Eur Respir J"},{"key":"2024102404130100000_32.168.230015.65","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"Laska","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102404130100000_32.168.230015.66","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00110-2020"},{"key":"2024102404130100000_32.168.230015.67","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00608-2020"},{"key":"2024102404130100000_32.168.230015.68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1164\/rccm.201809-1651OC","article-title":"Airway bacterial load and inhaled antibiotic response in bronchiectasis","volume":"200","author":"Sibila","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404130100000_32.168.230015.69","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01840-2021"},{"key":"2024102404130100000_32.168.230015.70","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01659-2015"},{"key":"2024102404130100000_32.168.230015.71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713901"},{"key":"2024102404130100000_32.168.230015.72","doi-asserted-by":"crossref","first-page":"2102899","DOI":"10.1183\/13993003.02899-2021","article-title":"Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD","volume":"59","author":"Vestbo","year":"2022","journal-title":"Eur Respir J"},{"key":"2024102404130100000_32.168.230015.73","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1513\/AnnalsATS.201804-245OC","article-title":"Association between inhaled corticosteroid use and pulmonary nontuberculous mycobacterial infection","volume":"15","author":"Liu","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2024102404130100000_32.168.230015.74","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00515-2020"},{"key":"2024102404130100000_32.168.230015.75","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02184-2021"},{"key":"2024102404130100000_32.168.230015.76","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03127-2021"},{"key":"2024102404130100000_32.168.230015.77","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1164\/rccm.202108-1943OC","article-title":"Endotyping COPD, bronchiectasis and the \u201cCOPD-bronchiectasis association\u201d","volume":"206","author":"Huang","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404130100000_32.168.230015.78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61452-X"},{"key":"2024102404130100000_32.168.230015.79","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02058-2018"},{"key":"2024102404130100000_32.168.230015.80","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-2600(20)30557-9","article-title":"The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study","volume":"9","author":"Dicker","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102404130100000_32.168.230015.81","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00018-2022"},{"key":"2024102404130100000_32.168.230015.82","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02269-2019"},{"key":"2024102404130100000_32.168.230015.83","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01293-2021"},{"key":"2024102404130100000_32.168.230015.84","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00769-2020"},{"key":"2024102404130100000_32.168.230015.85","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaci.2020.02.040","article-title":"The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease","volume":"147","author":"Dicker","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024102404130100000_32.168.230015.86","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00115-2017"},{"key":"2024102404130100000_32.168.230015.87","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015"},{"key":"2024102404130100000_32.168.230015.88","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01269-2018"},{"key":"2024102404130100000_32.168.230015.89","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01509-2019"},{"key":"2024102404130100000_32.168.230015.90","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03157-2020"},{"key":"2024102404130100000_32.168.230015.91","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/resp.12219","article-title":"The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis","volume":"19","author":"Goeminne","year":"2014","journal-title":"Respirology"},{"key":"2024102404130100000_32.168.230015.92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI95693"},{"key":"2024102404130100000_32.168.230015.93","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1164\/rccm.202108-1889OC","article-title":"Characterisation of eosinophilic bronchiectasis: a European multicohort study","volume":"205","author":"Shoemark","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404130100000_32.168.230015.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.09.023"},{"key":"2024102404130100000_32.168.230015.95","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/biomedicines9070772","article-title":"T2-high endotype and response to biological treatments in patients with bronchiectasis","volume":"9","author":"Oriano","year":"2021","journal-title":"Biomedicines"},{"key":"2024102404130100000_32.168.230015.96","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00453-2020"},{"key":"2024102404130100000_32.168.230015.97","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01333-2019"},{"key":"2024102404130100000_32.168.230015.98","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"key":"2024102404130100000_32.168.230015.99","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40262-022-01147-w","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of the dipeptidyl peptidase 1 inhibitor brensocatib for non-cystic fibrosis bronchiectasis","volume":"61","author":"Chalmers","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2024102404130100000_32.168.230015.100","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC"},{"key":"2024102404130100000_32.168.230015.101","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00303-2019"},{"key":"2024102404130100000_32.168.230015.102","doi-asserted-by":"crossref","first-page":"2001702","DOI":"10.1183\/13993003.01702-2020","article-title":"Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study","volume":"56","author":"Gramegna","year":"2020","journal-title":"Eur Respir J"},{"key":"2024102404130100000_32.168.230015.103","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00558-2020"},{"key":"2024102404130100000_32.168.230015.104","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ymthe.2020.02.001","article-title":"Precise targeting of miRNA sites restores CFTR activity in CF bronchial epithelial cells","volume":"28","author":"De Santi","year":"2020","journal-title":"Mol Ther"},{"key":"2024102404130100000_32.168.230015.105","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3390\/pharmaceutics14122754","article-title":"Recombinant alpha-1 antitrypsin as dry powder for pulmonary administration: a formulative proof of concept","volume":"14","author":"Bianchera","year":"2022","journal-title":"Pharmaceutics"},{"key":"2024102404130100000_32.168.230015.106","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01249-2022"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0015-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:05:55Z","timestamp":1740355555000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0015-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":106,"journal-issue":{"issue":"168","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,6,30]]}},"alternative-id":["10.1183\/16000617.0015-2023"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0015-2023","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]}}}